

# Evanthia Diamanti-Kandarakis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11632374/evanthia-diamanti-kandarakis-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107  
papers

13,795  
citations

48  
h-index

109  
g-index

109  
ext. papers

15,572  
ext. citations

5.4  
avg, IF

6.39  
L-index

#	Paper	IF	Citations
107	Endocrine-disrupting chemicals and PCOS: A novel contributor in the etiology of the syndrome <b>2022</b> , 227-244		0
106	Tailoring treatment for PCOS phenotypes. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2021</b> , 16, 9-18	4.1	4
105	Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 255-274	5.5	38
104	Implications and Future Perspectives of AGEs in PCOS Pathophysiology. <i>Trends in Endocrinology and Metabolism</i> , <b>2019</b> , 30, 150-162	8.8	23
103	Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 388	5.7	15
102	The role of stress in PCOS. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2017</b> , 12, 87-95	4.1	12
101	MECHANISMS IN ENDOCRINOLOGY: Nutrition as a mediator of oxidative stress in metabolic and reproductive disorders in women. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, R79-R99	6.5	23
100	Is there an association between thyroid function abnormalities and breast cancer?. <i>Archives of Endocrinology and Metabolism</i> , <b>2017</b> , 61, 54-61	2.2	16
99	Polycystic ovary syndrome and environmental toxins. <i>Fertility and Sterility</i> , <b>2016</b> , 106, 948-58	4.8	81
98	Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat model Peer review under responsibility of Alexandria University Faculty of Medicine. View all notes Available online 8 August 2015 View all notes. <i>Alexandria Journal of Medicine</i> , <b>2016</b> , 52, 159-168	0.7	
97	MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. <i>European Journal of Endocrinology</i> , <b>2016</b> , 175, R157-69	6.5	18
96	Advanced glycation end-products and insulin signaling in granulosa cells. <i>Experimental Biology and Medicine</i> , <b>2016</b> , 241, 1438-45	3.7	35
95	Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2-NF- $\kappa$ B and JNK-AP-1 signaling pathways. <i>Cellular and Molecular Life Sciences</i> , <b>2016</b> , 73, 1685-98	10.3	47
94	Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1564-73	12.7	34
93	Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. <i>Nature Communications</i> , <b>2015</b> , 6, 7502	17.4	214
92	Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial. <i>Stress</i> , <b>2015</b> , 18, 57-66	3	49
91	Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2015</b> , 16, 365-71	10.5	59

90	Targets to treat metabolic syndrome in polycystic ovary syndrome. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 1561-74	6.4	23
89	White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandrogenemia. <i>Hormones</i> , <b>2015</b> , 14, 91-100	3.1	11
88	Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , <b>2014</b> , 81, 426-31	3.4	28
87	Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. <i>Endocrine</i> , <b>2014</b> , 47, 631-8	4	46
86	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, P1-29	6.5	346
85	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 489-98	6.5	61
84	Polycystic ovary syndrome--phenotypes and diagnosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2014</b> , 244, 18-22; discussion 21	2	20
83	Impact of diet-induced obesity in male mouse reproductive system: The role of advanced glycation end product-receptor for advanced glycation end product axis. <i>Experimental Biology and Medicine</i> , <b>2014</b> , 239, 937-947	3.7	5
82	Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). <i>Hormones</i> , <b>2014</b> , 13, 65-73	3.1	59
81	The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. <i>Hormones</i> , <b>2014</b> , 13, 488-97	3.1	10
80	Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome. <i>Current Obesity Reports</i> , <b>2014</b> , 3, 377-86	8.4	8
79	Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 301-9	6.5	33
78	Endocrine disruptors and polycystic ovary syndrome: a focus on Bisphenol A and its potential pathophysiological aspects. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2014</b> , 17, 137-44	1.3	6
77	Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. <i>Fertility and Sterility</i> , <b>2013</b> , 99, 943-50	4.8	28
76	Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , <b>2013</b> , 168, R33-43	6.5	16
75	Novel insights into the pathophysiology and treatment of polycystic ovary syndrome <b>2013</b> , 2-4		
74	Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. <i>Anemia</i> , <b>2013</b> , 2013, 617204	1.6	31
73	Novel insights into the pathophysiology of PCOS: the role of environmental toxins <b>2013</b> , 38-48		1

72	The effects of old, new and emerging medicines on metabolic aberrations in PCOS. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2012</b> , 3, 27-47	4.5	75
71	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. <i>Endocrine Reviews</i> , <b>2012</b> , 33, 981-1030	27.2	928
70	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. <i>Endocrine</i> , <b>2012</b> , 42, 526-34	4	19
69	Insulin resistance and polycystic ovary syndrome through life. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5569-76	3.3	30
68	Phenotypes and enviromental factors: their influence in PCOS. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 270-82	3.3	61
67	Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, E480-4	5.6	238
66	Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander?. <i>Hormones</i> , <b>2011</b> , 10, 292-7	3.1	25
65	PCOS Forum: research in polycystic ovary syndrome today and tomorrow. <i>Clinical Endocrinology</i> , <b>2011</b> , 74, 424-33	3.4	102
64	Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. <i>Clinical Endocrinology</i> , <b>2011</b> , 75, 698-703	3.4	33
63	Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. <i>Journal of Bone and Mineral Metabolism</i> , <b>2011</b> , 29, 201-6	2.9	25
62	The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 908-21	3.3	8
61	Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , <b>2010</b> , 162, 193-212	6.5	155
60	Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 2038-49	5.6	669
59	Metformin in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1205, 192-8	6.5	64
58	Androgens associated with advanced glycation end-products in postmenopausal women. <i>Menopause</i> , <b>2010</b> , 17, 1182-7	2.5	22
57	PCOS in adolescents. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2010</b> , 24, 173-83	4.6	48
56	Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. <i>Journal of Cellular and Molecular Medicine</i> , <b>2010</b> , 14, 2460-9	5.6	42
55	In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. <i>Hormones</i> , <b>2009</b> , 8, 199-206	3.1	37

54	Metabolic syndrome and polycystic ovary syndrome... and vice versa. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2009</b> , 53, 227-37		40
53	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. <i>Fertility and Sterility</i> , <b>2009</b> , 91, 456-88	4.8	1268
52	Insulin Resistance in PCOS <b>2009</b> , 35-61		14
51	Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. <i>Kidney and Blood Pressure Research</i> , <b>2009</b> , 32, 24-31	3.1	13
50	Endocrine-disrupting chemicals: an Endocrine Society scientific statement. <i>Endocrine Reviews</i> , <b>2009</b> , 30, 293-342	27.2	2820
49	Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , <b>2009</b> , 160, 847-53	6.5	48
48	Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , <b>2008</b> , 69, 634-41	3.4	137
47	Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , <b>2008</b> , 10, e3	6.7	174
46	Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. <i>Women's Health</i> , <b>2008</b> , 4, 583-94	3	45
45	Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2008</b> , 109, 242-6	5.1	62
44	Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?. <i>European Journal of Endocrinology</i> , <b>2008</b> , 158, 525-31	6.5	30
43	Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. <i>Human Reproduction</i> , <b>2008</b> , 23, 1439-46	5.7	59
42	Insulin Sensitizers Targeting Metabolic and Reproductive Consequences in Polycystic Ovary Syndrome <b>2008</b> , 197-215		1
41	Does polycystic ovary syndrome start in childhood?. <i>Pediatric Endocrinology Reviews</i> , <b>2008</b> , 5, 904-11	1.1	16
40	Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , <b>2007</b> , 56, 129-34	12.7	60
39	Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. <i>Clinical Endocrinology</i> , <b>2007</b> , 67, 735-42	3.4	119
38	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. <i>Journal of Molecular Medicine</i> , <b>2007</b> , 85, 1413-20	5.5	73
37	Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. <i>Histochemistry and Cell Biology</i> , <b>2007</b> , 127, 581-9	2.4	125

36	Pathophysiology and types of dyslipidemia in PCOS. <i>Trends in Endocrinology and Metabolism</i> , <b>2007</b> , 18, 280-5	8.8	174
35	Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , <b>2007</b> , 66, 103-9	3.4	26
34	Pharmaceutical Intervention in Metabolic and Cardiovascular risk Factors in Polycystic Ovary Syndrome <b>2007</b> , 431-449		1
33	Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. <i>Human Reproduction</i> , <b>2006</b> , 21, 1426-31	5.7	193
32	Update on polycystic ovary syndrome. <i>Women's Health</i> , <b>2006</b> , 2, 561-9	3	2
31	Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4237-45	5.6	1491
30	Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , <b>2006</b> , 55, 494-500	12.7	31
29	Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. <i>Fertility and Sterility</i> , <b>2006</b> , 85, 420-7	4.8	84
28	Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , <b>2006</b> , 85, 1778-83	4.8	67
27	Molecular mechanisms of insulin resistance in polycystic ovary syndrome. <i>Trends in Molecular Medicine</i> , <b>2006</b> , 12, 324-32	11.5	199
26	Indices of low-grade inflammation in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1092, 175-86	6.5	79
25	Stress in women: metabolic syndrome and polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1083, 54-62	6.5	18
24	Insulin resistance in PCOS. <i>Endocrine</i> , <b>2006</b> , 30, 13-7		92
23	The role of genes and environment in the etiology of PCOS. <i>Endocrine</i> , <b>2006</b> , 30, 19-26		98
22	Polycystic ovary syndrome: the influence of environmental and genetic factors. <i>Hormones</i> , <b>2006</b> , 5, 17-34	3.1	76
21	Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. <i>Hormones</i> , <b>2006</b> , 5, 126-36	3.1	28
20	Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. <i>Sports Medicine</i> , <b>2005</b> , 35, 831-40	10.6	45
19	Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. <i>Human Reproduction</i> , <b>2005</b> , 20, 2127-32	5.7	39

18	Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , <b>2005</b> , 62, 37-43	3.4	129
17	Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1691-7	5.5	101
16	Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. <i>Human Reproduction Update</i> , <b>2005</b> , 11, 631-43	15.8	117
15	The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. <i>European Journal of Endocrinology</i> , <b>2004</b> , 150, 793-8	6.5	64
14	Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 1273-6	5.6	127
13	Hormone replacement therapy and risk of malignancy. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2004</b> , 16, 73-8	2.4	22
12	Hormones in sports: growth hormone abuse. <i>Hormones</i> , <b>2004</b> , 3, 37-45	3.1	3
11	A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1927-32	5.6	129
10	Conservative management of gynecologic diseases: insulin sensitizing agents in polycystic ovary syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 997, 322-9	6.5	3
9	Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma. <i>Cancer</i> , <b>2003</b> , 97, 12-20	6.4	7
8	Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. <i>Hormones</i> , <b>2003</b> , 2, 61-6	3.1	16
7	Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 4666-73	5.6	173
6	Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , <b>2000</b> , 73, 735-41	4.8	83
5	A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 4006-11	5.6	792
4	How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 623-9	5.2	4
3	The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2699-705	5.6	116
2	New perspectives in polycystic ovary syndrome. <i>Trends in Endocrinology and Metabolism</i> , <b>1996</b> , 7, 267-71	18.8	51
1	The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome		30

